A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

This study is testing a treatment approach for primary plasma cell leukemia — a rare and aggressive blood cancer — in patients who cannot undergo a stem cell transplant. Patients receive an induction regimen (bortezomib, lenalidomide, and dexamethasone) followed by CAR-T cell therapy targeting BCMA (a protein on cancer cells). **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with primary plasma cell leukemia (confirmed by blood tests showing at least 5% or 2 billion circulating cancer plasma cells) - You have measurable disease in your blood or urine - You are not eligible for high-dose chemotherapy with stem cell transplant (e.g., due to older age, organ problems, or frailty) **You may NOT be eligible if...** - You have previously received treatment for plasma cell leukemia - You have significant organ damage that prevents safe administration of the drugs - You have active infections or serious autoimmune disease Talk to your doctor to see if this trial is right for you.